Surrozen secures FDA clearance for SZN-8141 and $95.1 million financing

Surrozen, Inc. (NASDAQ:SRZN) given average recommendation of "Moderate Buy" by brokerages. September 18, 2026 Key points. * Analyst sentiment is moderately positive: Seven brokerages give Surrozen an average "Moderate Buy" rating, with four buys, one strong buy, one hold and one sell. The average 12-month price target is $45, including recent targets of $51 from William Blair and $44 from HC Wainwright. * Surrozen's latest quarterly results exceeded expectations: The company reported a loss of $0.41 per share versus the consensus estimate of a $1.29 loss, while revenue reached $5.0 million compared with analysts' $0.47 million forecast. * The stock remains well below recent highs: Shares opened at $16.94, compared with a 52-week range of $11.39 to $35.00, and traded below both their 50-day and 200-day moving averages. Institutional investors own 66.57% of the company, while a major shareholder recently sold 325,000 shares. * Five stocks to consider instead of Surrozen. Shares of Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $45.00. Several research analysts recently commented on the stock. William Blair assumed coverage on shares of Surrozen in a report on Thursday, August 20th. They set an "outperform" rating and a $51.00 target price for the company. Zacks Research upgraded shares of Surrozen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Surrozen in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $44.00 target price on shares of Surrozen in a research report on Monday, August 10th. Surrozen stock performance. NASDAQ:SRZN opened at $16.94 on Friday. The stock has a 50-day simple moving average of $21.94 and a 200 day simple moving average of $25.15. Surrozen has a 52-week low of $11.39 and a 52-week high of $35.00. The company has a market cap of $196.67 million, a PE ratio of -0.42 and a beta of 0.56. Surrozen (NASDAQ:SRZN - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($1.29) by $0.88. The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $0.47 million. Insider buying and selling at Surrozen. In other news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the company's stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the sale, the insider owned 574,047 shares in the company, valued at $12,198,498.75. This represents a 36.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 31.74% of the stock is owned by company insiders. Hedge funds weigh in on Surrozen. Several hedge funds and other institutional investors have recently made changes to their positions in the company. Spruce Street Capital LP acquired a new position in Surrozen during the fourth quarter worth approximately $9,764,000. 5AM Venture Management LLC grew its position in shares of Surrozen by 25.0% in the fourth quarter. 5AM Venture Management LLC now owns 387,500 shares of the company's stock valued at $8,758,000 after purchasing an additional 77,500 shares during the last quarter. Perceptive Advisors LLC bought a new position in shares of Surrozen during the first quarter worth approximately $6,682,000. Empery Asset Management LP bought a new position in shares of Surrozen during the fourth quarter worth approximately $2,350,000. Finally, Eversept Partners LP lifted its holdings in Surrozen by 23.8% during the 4th quarter. Eversept Partners LP now owns 95,286 shares of the company's stock worth $2,153,000 after purchasing an additional 18,289 shares during the last quarter. 66.57% of the stock is owned by institutional investors. About Surrozen. Surrozen, Inc is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen's approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body. Discover more Self-Help & Motivational Cryptocurrency News The company's product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Surrozen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list. While Surrozen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat

Surrozen announces submission of IND application for SZN-8141 for the treatment of diabetic macular edema. September 08, 2026 08:30 ET | Source: Surrozen, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) - Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody, for the treatment of diabetic macular edema (DME). "By bringing together these mechanisms, SZN-8141 is designed to both address vascular leakage and promote retinal vascular integrity. We are excited to..." "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular disease by combining two complementary mechanisms, activation of..." "By bringing together these mechanisms, SZN-8141 is designed to both address vascular leakage and promote retinal vascular integrity. We are excited to..." "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular disease by combining two complementary mechanisms, activation of..." "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular disease by combining two complementary mechanisms, activation of the Wnt pathway and inhibition of VEGF, in a single molecule," said Craig Parker, Chief Executive Officer of Surrozen. "By bringing together these mechanisms, SZN-8141 is designed to both address vascular leakage and promote retinal vascular integrity. We are excited to advance SZN-8141 into clinical development and evaluate this approach in patients with diabetic macular edema in the DUET Phase 1b/2a study." In preclinical studies, SZN-8141 demonstrated superior biological activity in reducing neovascularization and promoting retinal revascularization compared with either Wnt agonist or anti-VEGF monotherapy in a rodent model of retinal vascular disease. SZN-8141 also demonstrated greater reductions in vascular leakage than anti-VEGF therapy in a rodent model of neovascular age-related macular degeneration. SZN-8141 will be evaluated in a Phase 1b/2a clinical trial in DME called DUET, designed to assess safety, tolerability, and early signs of biological and clinical activity. Surrozen expects to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, with initial data anticipated in the second half of 2027. About SZN-8141 for Retinal Diseases Surrozen is developing SZN-8141 for the treatment of DME and neovascular age-related macular degeneration (wet AMD). SZN-8141 combines Frizzled 4 (FZD4)-mediated Wnt agonism and VEGF antagonism and has the potential to provide benefits over treatment with single mechanism agents against these targets. The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF therapies, including monotherapies and dual-pathway agents targeting VEGF and Ang-2. In addition, Merck's MK-3000, a FZD4-mediated Wnt agonist monotherapy, has demonstrated proof of concept in DME in a clinical trial. We believe SZN-8141 has the potential to treat multiple retinopathy indications and be differentiated from existing therapies. Data generated in preclinical models of retinopathy demonstrated that SZN-8141 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth. About Surrozen Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as "will," "plan," "intend," "potential," "expect," "could," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen's discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, such as the Company's plan to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, the availability of data, such as initial data from the DUET study being anticipated in the second half of 2027, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company's ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen's ability to identify, develop and commercialize drug candidates; Surrozen's ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen's Annual Report on Form 10-K for the year ended December 31, 2025, and Surrozen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the Securities and Exchange Commission ("SEC") under the heading "Risk Factors," and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen's expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.